Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1993 Jun;69(6):492–495. doi: 10.1136/hrt.69.6.492

Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction.

R M Norris 1, H D White 1, D B Cross 1, K S Woo 1, A H Maslowski 1, M P Caruana 1, H H Hart 1, B Williams 1
PMCID: PMC1025158  PMID: 8343314

Abstract

OBJECTIVE--To investigate the hypothesis that the magnitude of the life saving effect of aspirin in the second international study of infarct survival (ISIS-2) trial cannot be explained solely by prevention of late reocclusion of the infarct related artery. The aim of this study was to discover whether or not aspirin in combination with streptokinase had an adjuvant thrombolytic effect. DESIGN--Aspirin (150 mg) or placebo was given at the start of streptokinase infusion to 200 patients seen within six hours of the start of prolonged ischaemic cardiac pain and ST segment elevation. All patients received active aspirin at three hours. Patency of the infarct related artery was assessed non-invasively by the normalised rise of creatine kinase activity at three hours after starting streptokinase in these 200 patients and in a further 52 patients who had already taken aspirin within one week of the start of infarction. MAIN OUTCOME MEASURE--Rise in creatine kinase activity from baseline to > or = 20% or < 20% of the peak rise of activity in blood taken at three hours after starting infusion of streptokinase. This correlates with patency or occlusion of the infarct related coronary artery at about 2.5 hours after starting streptokinase. RESULTS--Assessed in this way, patency of the infarct related artery was 60% in patients given aspirin, 63% in those given placebo, and 62% in patients who had already taken aspirin within one week of infarction. CONCLUSION--The magnitude of the life saving effect of aspirin remains unexplained. Further investigation is needed into the mechanism of action of antiplatelet treatment in relation to thrombolytic treatment.

Full text

PDF
495

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Basinski A., Naylor C. D. Aspirin and fibrinolysis. Lancet. 1988 Nov 19;2(8621):1188–1189. doi: 10.1016/s0140-6736(88)90250-4. [DOI] [PubMed] [Google Scholar]
  2. Cairns J. A., Gent M., Singer J., Finnie K. J., Froggatt G. M., Holder D. A., Jablonsky G., Kostuk W. J., Melendez L. J., Myers M. G. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369–1375. doi: 10.1056/NEJM198511283132201. [DOI] [PubMed] [Google Scholar]
  3. Chesebro J. H., Knatterud G., Roberts R., Borer J., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Hillis D., Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 Jul;76(1):142–154. doi: 10.1161/01.cir.76.1.142. [DOI] [PubMed] [Google Scholar]
  4. Coller B. S. Platelets and thrombolytic therapy. N Engl J Med. 1990 Jan 4;322(1):33–42. doi: 10.1056/NEJM199001043220107. [DOI] [PubMed] [Google Scholar]
  5. Fitzgerald D. J., Catella F., Roy L., FitzGerald G. A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988 Jan;77(1):142–150. doi: 10.1161/01.cir.77.1.142. [DOI] [PubMed] [Google Scholar]
  6. Gold H. K., Coller B. S., Yasuda T., Saito T., Fallon J. T., Guerrero J. L., Leinbach R. C., Ziskind A. A., Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988 Mar;77(3):670–677. doi: 10.1161/01.cir.77.3.670. [DOI] [PubMed] [Google Scholar]
  7. Hackett D., Davies G., Chierchia S., Maseri A. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. N Engl J Med. 1987 Oct 22;317(17):1055–1059. doi: 10.1056/NEJM198710223171704. [DOI] [PubMed] [Google Scholar]
  8. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  9. Moschos C. B., Haider B., De La Cruz C., Jr, Lyons M. M., Regan T. J. Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion. Circulation. 1978 Apr;57(4):681–684. doi: 10.1161/01.cir.57.4.681. [DOI] [PubMed] [Google Scholar]
  10. Norris R. M., White H. D., Cross D. B., Woo K. S., Elliott J. M., Twigden D., Williams B., Johnson R. N. Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis. Br Heart J. 1993 Jun;69(6):485–491. doi: 10.1136/hrt.69.6.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Norris R. M., Whitlock R. M., Barratt-Boyes C., Small C. W. Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. Circulation. 1975 Apr;51(4):614–620. doi: 10.1161/01.cir.51.4.614. [DOI] [PubMed] [Google Scholar]
  12. Rivers J. T., White H. D., Cross D. B., Williams B. F., Norris R. M. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol. 1990 Aug;16(2):340–348. doi: 10.1016/0735-1097(90)90583-b. [DOI] [PubMed] [Google Scholar]
  13. Rosalki S. B. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med. 1967 Apr;69(4):696–705. [PubMed] [Google Scholar]
  14. Roux S., Christeller S., Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol. 1992 Mar 1;19(3):671–677. doi: 10.1016/s0735-1097(10)80290-6. [DOI] [PubMed] [Google Scholar]
  15. Ruf W., Suehiro G. T., Suehiro A., McNamara J. J. Regional myocardial blood flow in experimental myocardial infarction after pretreatment with aspirin. J Am Coll Cardiol. 1986 May;7(5):1057–1062. doi: 10.1016/s0735-1097(86)80223-6. [DOI] [PubMed] [Google Scholar]
  16. Sobel B. E., Bresnahan G. F., Shell W. E., Yoder R. D. Estimation of infarct size in man and its relation to prognosis. Circulation. 1972 Oct;46(4):640–648. doi: 10.1161/01.cir.46.4.640. [DOI] [PubMed] [Google Scholar]
  17. Verheugt F. W., van der Laarse A., Funke-Küpper A. J., Sterkman L. G., Galema T. W., Roos J. P. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol. 1990 Aug 1;66(3):267–270. doi: 10.1016/0002-9149(90)90833-m. [DOI] [PubMed] [Google Scholar]
  18. White H. D., Norris R. M., Brown M. A., Takayama M., Maslowski A., Bass N. M., Ormiston J. A., Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987 Oct 1;317(14):850–855. doi: 10.1056/NEJM198710013171402. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES